

Supplementary Information

Identification of Histamine H₃ Receptor Ligands Using a New Crystal Structure Fragment-based Method



Ida Osborn Frandsen[#], Michael W. Boesgaard[#], Kimberley Fidom, Alexander S. Hauser,
Vignir Isberg, Hans Bräuner-Osborne, Petrine Wellendorph^{*} and David E. Gloriam^{*}

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of
Copenhagen, Denmark

[#]These authors contributed equally

^{*} Corresponding authors.

Supplementary Table 1: The fragments used to build the H₃ pharmacophore. The selected representative fragments for H₃ yielded 9 pharmacophore elements and a tenth, for 5.46x461, was added based on docking of reference ligand structures in a H₃ structure model. The aromatic pharmacophore elements are based on multiple fragments and were manually placed in their midst. The pharmacophore element types are abbreviated; Ar: aromatic, HBA: hydrogen bond acceptor, HBD: hydrogen bond donor, HYD: hydrophobic and ICT: ionic cation. *Residue positions are indexed using the GPCRdb scheme for generic residue numbering¹, which is the Ballesteros-Weinstein scheme² adjusted for helical bulges and constrictions observed in crystal structures.

Residue Position*	GPCR	PDB ID	Ligand Moiety	Element (Fig. 1)	Element Type	Size (Å) / Tolerance
W3.28	ADRB1	2Y00, 4AMJ		R9	Ar	1.5
D3.32	5-HT1B	4IAR		D1	HBD	1.0
				P4	ICT	0.75
	ADRB1	2Y03		D2	HBD	1.0
				P5	ICT	0.75
Y3.33	M3	4DAJ		R8	Ar / HYD	1.5
	M2	3UON				
	H1	3RZE				
Y6.51	ADRB1	2Y00, 2Y03, 2T04				
E5.46x461	H3	-		P6	ICT	0.75
				D3	HBD	1.0
				R10	Ar	1.5
W6.48	H1	3RZE		R7	Ar	1.5

Supplementary Table 2: Additional results from the IP-one assay

Compound	pIC ₅₀ ±SEM	IC ₅₀ (μM)	n
21	4.68±0.10	20.9	5
42	4.38±0.11	42.1	5
64	3.58±0.17	261	4
68	4.66±0.20	22.0	2
75	3.92±0.18	121	3

Supplementary Table 3: Additional results from the radioligand competition binding assay

Compound	pKi±SEM	Ki (μM)	n
9^c	5.76±0.25	1.75	3
20^c	5.37±0.12	4.24	3
21^a	-	>50.0	3
42^b	4.83±0.08	14.8	4
44^b	5.55±0.06	2.82	3
64	4.06±0.11	86.7	3
67	5.45±0.19	3.52	3
68^a	-	>300	3
75	5.32±0.04	4.82	3

a Compound had little to no effect on radiolabeled ligand binding in the concentrations examined.

b Compound unable to outcompete radiolabeled ligand to NSB levels (non-competitive interaction).


c A continued decrease in potency observed upon repeated experimentation, possibly due to compound breakdown.


Ki values obtained by the method of Cheng-Prusoff using a K_d value of 0.15 nM for [3H]N-α-methylhistamine.

Supplementary Table 4: Filtering criteria for the eMolecule compounds


Parameter	Range
Molecular weight	200 - 500
Rotatable bonds	2 - 10
Rings	≤ 5
Aromatic carbons	≥ 6
Aliphatic rings	≤ 2
State penalty (Epik)	≤ 2
Reactive groups (#rtvFG)	0
Polar surface area (PSA)	< 150
Hydrophilic component of the solvent accessible surface area (FISA)	7 - 330
Predicted solubility (PlogS)	-6 - 0.5
Predicted logP (PlogPo/w)	< 5
Hydrogen bond acceptors	1 - 10
Hydrogen bond donors	1 - 5
Charged donor groups	≥ 1
Charged amines	1 - 3
Neutral amines	≤ 1
Total charge	2
Number of negative atoms	0

Supplementary Chart 1: Structures of the purchased pharmacophore hits (1-44) and primary assaying hit analogs (45-76). The 2D structures were drawn in ChemBioDraw v. 14.0.







ID: 83352918




ID: 17412505




ID: 96256639




ID: Z1333147743




ID: Z840220692




ID: 51422595




ID: 80792003




ID: Z1139559799




ID: 52135995




ID: 23270094




ID: 20073354




ID: Z840089412




ID: 74699548




ID: 82687728




ID: Z107728962




ID: Z343568958




ID: Z401947192




ID: 45040604



ID: 43911446




ID: 67481612




41

ID: 73088155




42

ID: STK530530




43

ID: PB653173258




44

ID: Z371469800




45

ID: STOCK6S-35722




46

ID: 14144947




47

ID: STOCK3S-02044




48

ID: Z31252931




49

ID: 99314199




50

ID: 87627023




51

ID: 42681880




52

ID: 90452752




53

ID: 38644162




54

ID: 84865704




55

ID: STK167540




56

ID: 48840451




57

ID: 90940961




58

ID: 49988324




59

ID: 11893028




60


ID: 65933140




61




62



63



64



65


ID: 68828179

ID: STK790098

ID: STK356705


ID: 21263926

ID: 13575804




66

ID: 49065533




67

ID: 97882939




68

ID: Z104342908




69

ID: 90400697




70

ID: 27779432




71

ID: 61725337




72

ID: 13841841




73

ID: STOCK1N-72923




74

ID: STOCK1S-32262



75

ID: STOCK2S-10418



76

ID: STOCK2S-12725

References

- 1 Isberg, V. *et al.* Generic GPCR residue numbers - aligning topology maps while minding the gaps. *Trends Pharmacol. Sci.* **36**, 22-31, doi:10.1016/j.tips.2014.11.001 (2015).
- 2 Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods Neurosci.* **25**, 366-428, doi:[http://dx.doi.org/10.1016/S1043-9471\(05\)80049-7](http://dx.doi.org/10.1016/S1043-9471(05)80049-7) (1995).